Skip to main content
. 2017 Dec 12;131(8):888–898. doi: 10.1182/blood-2017-08-802470

Table 2.

Summary of responses

Response category PTCL (n = 16) CTCL (n = 19)
ORR (CR + PR)
 ORR, n (%) 8 (50.0) 6 (31.6)
 95% Confidence interval (CI) (24.7, 75.3) (12.6, 56.6)
Best overall response, n (%)
 CR 3 (18.8) 0
 PR 5 (31.3) 6 (31.6)
 Stable disease 1 (6.3) 6 (31.6)
 Progressive disease 6 (37.5) 6 (31.6)
 Unknown 1 (6.3) 1 (5.3)
Time to response, median months (range) 1.9 (1.6-3.5) 2.4 (1.6-3.8)
PFS, median months (95% CI) 8.3 (1.4, NR) 4.5 (1.0-13.8)
OS, median months (95% CI) 8.4 (4.3, NR) NR (18.6, NR)

The Clopper-Pearson CI is presented. Patients with no postbaseline response assessment are represented as having an “unknown” response. Percentages are based on the number of patients in each indication.

NR, not reached at the time of this analysis; PR, partial response.